Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Treatment monitoring of HIV-infected patients based on mechanistic models

M. Prague, D. Commenges, J. Drylewicz, R. Thiébaut,

. 2012 ; 68 (3) : 902-11.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc13012505
E-zdroje Online Plný text

NLK Medline Complete (EBSCOhost) od 2003-03-01 do Před 1 rokem
Wiley Online Library (archiv) od 1999-01-01 do 2012-12-31

For most patients, the HIV viral load can be made undetectable by highly active antiretroviral treatments highly active antiretroviral therapy: the virus, however, cannot be eradicated. Thus, the major problem is to try to reduce the side effects of the treatment that patients have to take during their life time. We tackle the problem of monitoring the treatment dose, with the aim of giving the minimum dose that yields an undetectable viral load. The approach is based on mechanistic models of the interaction between virus and the immune system. It is shown that the "activated cells model," allows making good predictions of the effect of dose changes and, thus, could be a good basis for treatment monitoring. Then, we use the fact that in dynamical models, there is a nontrivial equilibrium point, that is with a virus load larger than zero, only if the reproductive number R(0) is larger than one. For reducing side effects, we may give a dose just above the critical dose corresponding to R(0) equal to 1. A prior distribution of the parameters of the model can be taken as the posterior arising from the analysis of previous clinical trials. Then the observations for a given patient can be used to dynamically tune the dose so that there is a high probability that the reproductive number is below one. The advantage of the approach is that it does not depend on a cost function, weighing side effects and efficiency of the drug. It is shown that it is possible to approach the critical dose if the model is correct. A sensitivity analysis assesses the robustness of the approach.

000      
00000naa a2200000 a 4500
001      
bmc13012505
003      
CZ-PrNML
005      
20130415094101.0
007      
ta
008      
130404s2012 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)22934714
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Prague, Mélanie $u University of Bordeaux, ISPED, Centre INSERM U897-Épidémiologie-Biostatistique, F-33000 Bordeaux, France. melanie.prague@isped.u-bordeaux2.fr
245    10
$a Treatment monitoring of HIV-infected patients based on mechanistic models / $c M. Prague, D. Commenges, J. Drylewicz, R. Thiébaut,
520    9_
$a For most patients, the HIV viral load can be made undetectable by highly active antiretroviral treatments highly active antiretroviral therapy: the virus, however, cannot be eradicated. Thus, the major problem is to try to reduce the side effects of the treatment that patients have to take during their life time. We tackle the problem of monitoring the treatment dose, with the aim of giving the minimum dose that yields an undetectable viral load. The approach is based on mechanistic models of the interaction between virus and the immune system. It is shown that the "activated cells model," allows making good predictions of the effect of dose changes and, thus, could be a good basis for treatment monitoring. Then, we use the fact that in dynamical models, there is a nontrivial equilibrium point, that is with a virus load larger than zero, only if the reproductive number R(0) is larger than one. For reducing side effects, we may give a dose just above the critical dose corresponding to R(0) equal to 1. A prior distribution of the parameters of the model can be taken as the posterior arising from the analysis of previous clinical trials. Then the observations for a given patient can be used to dynamically tune the dose so that there is a high probability that the reproductive number is below one. The advantage of the approach is that it does not depend on a cost function, weighing side effects and efficiency of the drug. It is shown that it is possible to approach the critical dose if the model is correct. A sensitivity analysis assesses the robustness of the approach.
650    _2
$a algoritmy $7 D000465
650    _2
$a látky proti HIV $x aplikace a dávkování $x škodlivé účinky $7 D019380
650    12
$a vysoce aktivní antiretrovirová terapie $x škodlivé účinky $7 D023241
650    _2
$a biometrie $7 D001699
650    _2
$a CD4-pozitivní T-lymfocyty $x účinky léků $x imunologie $x virologie $7 D015496
650    _2
$a klinické zkoušky jako téma $x statistika a číselné údaje $7 D002986
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a monitorování léčiv $x statistika a číselné údaje $7 D016903
650    _2
$a HIV infekce $x farmakoterapie $x imunologie $x virologie $7 D015658
650    _2
$a lidé $7 D006801
650    _2
$a biologické modely $7 D008954
650    _2
$a modely imunologické $7 D018448
650    12
$a statistické modely $7 D015233
650    _2
$a virová nálož $x účinky léků $7 D019562
655    _2
$a časopisecké články $7 D016428
700    1_
$a Commenges, Daniel $u -
700    1_
$a Drylewicz, Julia $u -
700    1_
$a Thiébaut, Rodolphe $u -
773    0_
$w MED00000765 $t Biometrics $x 1541-0420 $g Roč. 68, č. 3 (2012), s. 902-11
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22934714 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130404 $b ABA008
991    __
$a 20130415094335 $b ABA008
999    __
$a ok $b bmc $g 975703 $s 810786
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 68 $c 3 $d 902-11 $i 1541-0420 $m Biometrics $n Biometrics $x MED00000765
LZP    __
$a Pubmed-20130404

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...